NCT07789119Recruiting
Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50000 (estimated)
- First submitted
- 18 Aug 2026
- Start date
- 10 Sept 2026
- Primary completion date
- 31 Dec 2036
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Bladder cancer
- NCT number
- NCT07789119
What you commit to
- Study type: Observational
- Planned participants: 50000
- From 10 Sept 2026 to the primary completion date, 31 Dec 2036
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives.
Age
- Age younger than 18 years.
Other
- Unable to understand the study information or unable to personally provide informed consent.
- Declines participation.
- Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately.
- Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.
Criteria the registry did not label
- Eligibility Criteria
- Participants must meet all of the following criteria for enrollment:
- Age 18 years or older at the time of consent.
- Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy.
- Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations.
- Able to understand and personally provide informed consent.
- Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UT MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.